Nerve-Stimulating Device for Cancer Wasting Enters First Human Trial

A small device worn against the skin may soon change how medicine approaches one of the most feared complications of advanced cancer. The Terasaki Institute for Biomedical Innovation in Los Angeles announced on October 7, 2026 that OnVagus, a medical device company incubating at the Institute, has received institutional and regulatory approval to begin the first human trial of its noninvasive nerve-stimulation therapy for patients experiencing cancer-related wasting. The announcement marks a rare milestone in a field where, despite decades of research, no FDA-approved therapy currently exists for the condition known as cachexia.

Cachexia is a severe and progressive wasting syndrome characterized by unintentional weight loss and the erosion of skeletal muscle, and it affects a large proportion of patients with advanced cancers. Unlike ordinary weight loss, cachexia cannot be reversed simply by eating more or by nutritional supplementation alone. The syndrome involves deep metabolic disruption: inflammation, altered metabolism in the liver, and signals traveling between the brain and the body’s organs conspire to break down muscle tissue even when patients consume adequate calories. In patients with metastatic pancreatic cancer, cachexia is especially common and can become the factor that limits how long a person is able to continue chemotherapy, the treatment that offers the best chance of extending life.

The scale of the problem is sobering. Up to half of all cancer deaths are attributable to cachexia, making it a silent contributor to mortality that often goes unaddressed in treatment planning. Patients describe profound fatigue, loss of strength, and a body that seems to be consuming itself, while families watch loved ones grow frail in ways that chemotherapy alone cannot explain. Because no approved therapies exist, clinicians have been left with supportive care measures that ease symptoms but do not touch the underlying biology. This gap represents what researchers at the Terasaki Institute describe as a major unmet need, and it is precisely the gap that the OnVagus device is designed to address.

The technology takes an unusual approach. Rather than targeting tumors or immune cells directly, the OnVagus device delivers noninvasive electrical stimulation through the skin to modulate the vagus nerve, one of the body’s most important neural highways. The vagus nerve is the longest cranial nerve, connecting the brainstem to organs throughout the chest and abdomen, including the gut and the liver. Through this pathway, the brain constantly monitors and adjusts digestion, metabolism, and inflammatory responses. In cachexia, researchers believe that maladaptive signaling along this axis contributes to the metabolic derangement that drives muscle wasting. By intercepting and modulating those signals, the device aims to intervene in the pathobiology of the syndrome itself rather than merely its symptoms.

The scientific rationale for the approach was established in a preclinical study published last year in the journal Cell, which described both the device concept and its underlying mechanism. That work demonstrated the biological basis for using vagal modulation to influence the wasting process, laying the groundwork for translating the technology into something that could be tested in patients. According to the company, the OnVagus device is the first transcutaneous vagal block device designed for human use, meaning it works entirely through the skin without surgery, implants, or electrodes placed inside the body. This distinguishes it from other neuromodulation approaches that require invasive procedures, a significant consideration for patients whose health is already fragile.

Dr. Aliesha O’Raw, Terasaki Fellow and Co-Founder of OnVagus, emphasized the significance of the noninvasive design. The device, she said, allows the team to modulate the vagus nerve without surgery or implants, providing a new way to intervene in the biological processes driving cachexia. Moving from preclinical work into a first human trial, she noted, is an important step in finding out whether the approach can actually help patients. That transition, from mechanism studies in the laboratory to a device on a patient’s skin, is the kind of translation that medical research institutions aspire to but rarely achieve so directly.

The first step in the clinical program will be a safety lead-in trial enrolling ten pancreatic cancer patients with cachexia at MD Anderson Cancer Center in Houston, one of the world’s leading cancer treatment and research institutions. The first patient is expected to enroll in October. Over eight weeks, the study will assess the device’s safety and usability as its primary outcome, a cautious and appropriate starting point for any first-in-human neuromodulation technology. Secondary measures will include preliminary relief of cachectic symptoms and biomarkers such as liver function, an organ whose metabolic reprogramming is thought to be central to the wasting process. The trial will also collect exploratory measures of progression-free survival and overall survival, offering an early glimpse of whether the intervention might influence disease trajectory and not just body composition.

The trial is supported by a coalition of funders that reflects the multi-stage nature of translational research. Funding comes from the National Cancer Institute’s Small Business Innovation Research program, which supports early-stage medical technology companies; an NIH R01 award to MD Anderson; the American Cancer Society; and BrightEdge, the American Cancer Society’s investment arm. Dr. Xiling Shen, Acting Director of the Terasaki Institute for Biomedical Innovation, described the trial as exactly the kind of translation the Institute wants to see, from a fundamental discovery in the laboratory to a technology being tested in the clinic to help patients. The Institute, a non-profit research organization, focuses on developing biomaterials, cellular and tissue engineering, medical devices, and microfluidic systems, with an explicit mission to accelerate the movement of laboratory discoveries into real-world care.

If the initial safety and usability results are positive, with no serious adverse events observed, the team plans to launch a much larger and more definitive study: a year-long, 120-patient randomized, double-blind trial comparing the active device to a sham device. The sham-controlled design is critical for a neuromodulation therapy, because the placebo effect and the natural variability of cachexia progression could otherwise confound the results. In that pivotal trial, the primary outcome would be a composite measure combining extended time on chemotherapy with reduced cachectic weight loss, an endpoint that captures what matters most to patients, namely the ability to keep receiving effective treatment while preserving their bodies. Secondary measures will include activity levels, mood, and muscle retention, while exploratory measures will track liver function and neurotransmitter levels, potentially illuminating how the intervention works in humans.

For patients with metastatic pancreatic cancer, a disease with notoriously limited treatment options, the prospect of a noninvasive therapy that could preserve strength and quality of life during treatment, and potentially extend survival, is significant. The trial also represents a broader shift in how the medical community thinks about cachexia: not as an inevitable side effect of advanced cancer, but as a treatable condition with its own targetable biology. Much remains to be proven, of course. The safety lead-in is small, and the pivotal trial has not yet begun, so any benefit to patients will only be established through the rigorous clinical testing now getting underway. But the journey of this technology, from a discovery published in Cell to a device cleared for first-in-human testing at one of the world’s premier cancer centers, illustrates how fundamental neuroscience can be redirected toward one of oncology’s most stubborn unsolved problems. If the results hold, the simple act of modulating a nerve through the skin could become a new tool in the fight against the wasting that claims so many lives alongside cancer itself.

Subject of Research: Noninvasive vagus nerve stimulation for cancer cachexia

Article Title: New device targets nerve signals to treat cancer-related wasting, moving to first human trial

Article References: New device targets nerve signals to treat cancer-related wasting, moving to first human trial. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cachexia, vagus nerve, OnVagus, Terasaki Institute, pancreatic cancer, clinical trial, neuromodulation, MD Anderson, medical device, cancer wasting, NCI SBIR, translational research